Safety study of an RSV mRNA vaccine in healthy adults
Part of Immune system & allergy, Infections clinical trials.
This study tests a new RSV vaccine to see if it is safe for healthy adults. It uses mRNA technology to help your body build protection against RSV, a common respiratory virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are generally healthy with no serious long-term illnesses.
- You have not had an RSV infection in the last 6 months or ever received an RSV vaccine.
- If you could become pregnant, you agree to use effective birth control for 6 months after the vaccine.
- You do not have a fever (temperature above 99°F or 37°C) on the day of vaccination.
- You are not allergic to any ingredients in the vaccine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study will safely expose healthy older adults (65-75) to a mild RSV B virus to see how their immune system responds. It may help develop better vaccines or treatments for RSV in older people.
This study tests an experimental RSV vaccine (IN006) in healthy adults to check its safety and how well it triggers an immune response. It may help protect against respiratory syncytial virus (RSV), which can cause serious lung infections.
This study tests a new vaccine to protect against RSV (a common respiratory virus that causes cold-like illness, especially serious in older adults). The vaccine is made in laboratory cell cultures and includes an immune-boosting ingredient. Researchers want to see if it's safe and if it helps your body fight RSV infection.
This trial tests a new RSV vaccine in adults aged 60 and older to see if it is safe and helps the immune system fight RSV. If you are generally healthy or have stable medical conditions without recent infections or vaccines, you may be eligible.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This trial tests a new RSV vaccine in two phases. First, it will be given to healthy adults 18 and older to check safety. Then, it will be studied in adults 50 and older, including those with stable health conditions, to see if it helps protect against RSV, a common virus that can cause serious breathing problems in older people.
Hear when a new RSV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.